Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Neurodegeneration


The Neurodegeneration cluster portfolio consists of research on adult onset neurodegenerative diseases of all types, broadly focusing on pathogenesis, treatment and prevention. Research on the normal structure and function of neural systems is also included to enable identification of intervention strategies. The role of the programmatic team is to develop, implement and manage these research programs and to promote the translation of research findings into clinical practice.  Included in the portfolio are topics such as neuronal cell death, protein misfolding, aggregation, and  processing, mitochondrial pathologies, epidemiological studies, genetic studies including genome-wide association studies (GWAS), biomarker studies, clinical studies including deep brain stimulation and gene therapy and translational projects that will accelerate bench-to-bedside therapies for neurodegenerative disorders.

Quick Links

Workshop Summary

Neurodegeneration Funding Initiatives and Requests for Information

Neurodegeneration Program Staff

Scientific StaffResearch Area
Roderick Corriveau, Ph.D.
Program Director
Point of contact: AD, vascular dementias, hereditary spastic paraplegia
Alzheimer’s disease, vascular dementias, and hereditary spastic paraplesia. For Alzheimer’s disease research, studies focused on molecular mechanisms of disease pathophysiology with areas of emphasis including but not limited to: (1) APP, beta-amyloid, presenilins, tau, neurotrophins and synaptic proteins; (2) animal models; (3) neuroinflammation; (4) post-translational protein modifications; (5) protein trafficking and clearance.
  
Amelie Gubitz, Ph.D.
Program Director
Point of contact: ALS, SBMA (Kennedy's Disease), HSP
Basic, translational, and clinical research studies of amyotrophic lateral sclerosis (ALS), X-linked spinal and bulbar muscular atrophy (SBMA, Kennedy's Disease), and hereditary spastic paraplegia (HSP).
  
Beth-Anne Sieber, Ph.D.
Program Director
Point of contact: PD, parkinsonism, ET, dystonia
Parkinson’s disease (PD), including molecular biology, cell biology, neurochemistry, deep brain stimulation (DBS), gene therapy, motor and non-motor manifestations. Parkinsonian disorders including multiple system atrophy (MSA) and progressive supranuclear palsy (PSP); essential tremor; dystonia.
  
Margaret Sutherland, Ph.D.
Program Director
Point of contact: HD, FTD
Huntington’s Disease (HD), Frontotemporal dementia (FTD), Parkinson’s Disease (PD), genome-wide association (GWA) studies, genetics, biomarkers, stem cells, protein and mitochondrial dynamics, translational research, clinical trials
  
Andrey Kuzmichev Ph.D.
Health Program Specialist
 
  
Pamela Wernett, Ph.D.
Health Program Specialist
 
  

Address

Neuroscience Center
6001 Executive Blvd.
Bethesda, Maryland 20892